BioSpace News Archive

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark DREAM-HF Phase 3 randomized controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR ® ) in 537 patients with advanced chronic heart failure 1 . Over a mean 30 months of follow-up, patients with advanced chronic heart failure who received a single endomyocardial trea

Two skin screening clinics opened in November 2020, with more than 800 assessments on close to 500 patients completed to date using MedX’s DermSecure® platform

Boston Scientific Corporation announced that a stipulation of dismissal has been filed in the Nevro Corporation patent infringement case against Boston Scientific in the United States District Court for the Northern District of California.

Atlanta Oral & Facial Surgery and Bay Area Oral Surgery Management, both well-respected and nationally recognized oral surgery groups, announced that they have entered into a strategic partnership with Blue Sea Capital, a leading growth-oriented private equity firm, to form Beacon Oral Specialists and to position AOFS and BAOSM for continued expansion.

During height of coronavirus pandemic, nine rogue drug companies announce they are refusing to provide certain drugs at the legally required ‘340B price’ as required by section 340B of the U.S. Health Services Act

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced the pricing of its previously announced underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $20.00 per share

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increase

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the closing of its previously announced upsized underwritten public offering of 5,339,286 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 696,428 shares, at the

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced its financial results for the second fiscal quarter ended October 31, 2020. Second Quarter and Recent Highlights:

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an addi